Publications found:
13,148
Sort by:
Booming Biotech Market in India
US$ 800.00
Indian biotech sector is witnessing a quantum surge in terms of growth of the industry. The growth can be attributed to a large pool of scientific talent, world-class information technology industry,...
October 2011
100 pages
CIPLA, Para IV Upside To Continue: Its Lexapro After Zyprexa
US$ 350.00
... of $1b) under 180-day exclusivity starting 14 March 2012. Cipla remained an active partner to Ivax (now Teva) by developing ... -day exclusivity. Thus Cipla too will share the upsides from the exclusivity. We expect Cipla to gain $50m ... will start accruing immediately after the upside from Zyprexa API supply to Teva ...
October 2011
3 pages
Indian Natural Gas Sector Analysis
US$ 800.00
India’s primary energy basket is on the threshold of witnessing a quantum jump in contribution from natural gas to meet soaring domestic energy demand. Due to the inherent environment-friendly nature,...
September 2011
110 pages
Indian Power Sector Analysis
US$ 800.00
Being one of the fastest growing economies and the second largest populated country, India represents an attractive destination for the power industry. The working age population is increasing at a ra...
September 2011
105 pages
Indian Energy Sector 2011-2020: Economic and Risk Analysis, September 2011
US$ 2,490.00
... to Lucintel`s report "Indian Energy Sector 2011-2020: Economic and Risk Analysis", analyzes and identifies India`s energy sector and outlines its areas of opportunity in the coming decade. Energy consumption from ... to Lucintel’s report "Indian Energy Sector 2011-2020: Economic and Risk Analysis", analyzes and identifies India’s energy sector and outlines its areas of opportunity in the coming decade. Energy consumption from ...
September 2011
230 pages
Booming Clinical Trials Market in India
US$ 1,000.00
Single User PDF Format: US$ 1,000.00
Multi-User License: US$ 1,600.00
Hard Copy: US$ 1,200.00
CD-ROM: US$ 1,200.00 India has billion plus population and a home for various life threate...
August 2011
145 pages
Booming Consumer Electronics Market in India
US$ 800.00
Single User PDF Format: US$ 800.00
Multi-User License: US$ 1,100.00
Hard Copy: US$ 900.00
CD-ROM: US$ 900.00 The Indian consumer electronics industry has been growing at a double-digit...
August 2011
95 pages
Booming Generics Drug Market in India
US$ 1,000.00
Single User PDF Format: US$ 1,000.00
Multi-User License: US$ 1,800.00
Hard Copy: US$ 1,200.00
CD-ROM: US$ 1,200.00 The world has witnessed a sharp increase in the demand for cost-effec...
August 2011
60 pages
Indian Fast Food Market Analysis
US$ 800.00
Single User PDF Format: US$ 800.00 Multi-User License: US$ 1,200.00 Hard Copy: US$ 1,000.00 CD-ROM: US$ 1,000.00 The Indian fast food market has been witnessing rapid growth on the back of positive d...
August 2011
40 pages
India Solid Waste Management Analysis
US$ 800.00
Single User PDF Format: US$ 800.00 Multi-User License: US$ 1,100.00 Hard Copy: US$ 900.00 CD-ROM: US$ 900.00 India being the 7th largest country in terms of area and 2nd largest in terms of populatio...
August 2011
65 pages
Indian Cement Market Report: 2011 Edition
US$ 800.00
... and construction recovery. Even in the tough conditions, Indian cement industry has been able to sustain its growth. ... cement companies. The report analyzes the cement industry in India focusing on demand supply matrix in various regions. The report is aimed at providing a better understanding of the market ...
August 2011
45 pages
External Defibrillator market in India 2011
US$ 950.00
... description of the segments in the defibrillator market in India. The market overview section provides an insight into the market and highlights the market size and growth. Import ...
August 2011
32 pages
Hair Color Market in India 2011
US$ 950.00
... after order is placed. The hair color market in India is driven by growth in the need to not only cover grey hairs and look presentable but also ... also been highlighted. This is followed by an overview of the hair color market in India. The section talks of the market size and growth of the sector and provides ...
August 2011
38 pages
Aurobindo - Feeling The Heat of USFDA and Debt
US$ 140.00
We reiterate our Underperform rating on Aurobindo after Q1 FY12 result that remained ... (up by 39% and 20% of total sales) that included a Government of India tender where ARBP did not earn any profit. As expected ... API and formulations) remain at the core of ‘India advantage’. We reduce our target price to Rs.120
August 2011
6 pages
Ranbaxy - When Will The Base Business Stabilize?
US$ 140.00
We reiterate our Market Perform rating on Ranbaxy after the Q2 CY11 result that was in line with our ... about a possible timely launch. Longer term potential of Ranbaxy seems promising with Daiichi-Ranbaxy likely to become the largest generic company in Japan ...
August 2011
6 pages
Cipla - Margin Improvement - A Healthy Sign.
US$ 140.00
... higher than our earnings estimate owing to the sharp improvement in gross margin. The improvement in gross margin (up by 330 bps, Y-o-Y) is largely due to the ... day exclusivity and (2) improvement in margin as contribution from Indore facility increases. For the longer term, CIPLA’s traditional business model ...
August 2011
6 pages
IPCA- Margin Improvement, Despite Lower Domestic Sales
US$ 140.00
... sales in WHO member countries. We expect several growth drivers for Ipca in the near term. (1) US generics growth even without the ... WHO member countries and branded formulations (3) margin improvement as sales mix improves in favor of formulation sales. We see Ipca as the best bet in the domestic formulations ...
August 2011
5 pages
Sun Pharma- Strong Margin Indicates A Strong Product Portfolio
US$ 140.00
Sun Pharma’s Q1 FY12 result was largely in line with our ... performance was not quite upto the mark, however, EBITDA margin improved by 300 bps Q-o-Q (Y-o-Y not relevant owing to launch of ... peers in the pharma space due to its rich, highly probable and yet hidden Para IV pipeline, strong balance sheet, likely ...
August 2011
8 pages
Dishman - Moving away from CRAMS
US$ 140.00
Dishman’s Q1 FY12 result was below our expectations ... Amcis. The standalone EBITDA increased largely driven by sales from disinfectants in India, supply of intermediate of Brilinta to Astra Zeneca and ... most of them (except for Brilinta intermediate supply) coming from its non-CRAM business. On CRAMs part, we see ...
July 2011
5 pages
Lupin - Impact of Thin Pipeline Showing Up
US$ 140.00
... reiterate our Underperform with target price of `360 on Lupin after its Q1FY12 result that reflected a reduction in ... fag end of the quarter impacted the overall performance. We have always remained concerned about Lupin’s thin US pipeline along with a ... higher depreciation to eat into the earnings of Lupin.
July 2011
8 pages
Biocon – Uneventful Quarter – R&D Expense Yet To Rise
US$ 140.00
BIOS 4QFY11 result was below our expectations on sales (excluding licensing income), but met our earnings estimate largely due to a lower than expected R&D expense. Licensing income too remained below estimate as it remains lumpy. Surprisingly biopharma sales (ex licensing income) grew by a modest 9% mainly ...
July 2011
6 pages
Direct-to-Home (DTH) Market in India: 2011 Edition
US$ 800.00
Direct-to-Home (DTH) is a distribution platform for multichannel TV programs on KU band by using a satellite system which transmits signal directly to the subscriber’s premises. ... satellites and content. The major players in DTH market in India are Dish TV, Tata Sky, Sun Direct, Big TV, Airtel Digital TV and ...
July 2011
40 pages
CADILA HEALTHCARE LTD - In a Consolidation Phase
US$ 140.00
CDH’s Q1 FY12 adjusted result (adjusted to the milestone income from Abbott) was below our sales and earnings estimate. Higher base created in FY11 by pushing product sales last year to achieve the $1b sales mark was the main reason for a muted performance in most of the business divisions. While the ...
July 2011
6 pages
Para IV Pipeline Analysis of Indian Pharma Companies
US$ 400.00
... cliff of 2014, many of the Indian companies are choosing the Para IV route to grab a higher market share, both in value and volume ... world’s top 11 products under litigation. This report is a comprehensive study of Para IV pipeline of the Indian companies and likely upside from each of the ...
June 2011
214 pages
Indian Diagnostic Market Analysis
US$ 800.00
Single User PDF Format: US$ 800.00 Multi-User License: US$ 1400.00 Hard Copy: US$ 1000.00 CD-ROM: US$ 1000.00Indian diagnostics sector is witnessing an era of immense progress in innovative competenc...
June 2011
65 pages
Indian Education Services - A Hot Opportunity
US$ 900.00
Single User PDF Format: US$ 900.00 Multi-User License: US$ 1,500.00 Hard Copy: US$ 1,000.00 CD-ROM: US$ 1,000.00India has one of the largest higher education systems in the world. However, still ther...
June 2011
80 pages
Indian MVAS Market Forecast to 2014
US$ 800.00
Single User PDF Format: US$ 800.00 Multi-User License: US$ 1,200.00 Hard Copy: US$ 1,000.00 CD-ROM: US$ 1,000.00 India mobile value-added services (MVAS) market has been witnessing phenomenal growth...
June 2011
55 pages
India 3G Market Forecast to 2014
US$ 600.00
Single User PDF Format: US$ 600.00 Multi-User License: US$ 1,000.00 Hard Copy: US$ 700.00 CD-ROM: US$ 700.00 The Indian telecom industry has undergone a revolutionary change during the past few years...
June 2011
60 pages
Indian Tourism Industry Analysis
US$ 600.00
Single User PDF Format: US$ 600.00 Multi-User License: US$ 900.00 Hard Copy: US$ 700.00 CD-ROM: US$ 700.00 Indian tourism sector is one of the most crucial sectors of the economy in the country. It i...
June 2011
60 pages
Analyzing the Indian Retail Industry
US$ 450.00
... effort were low. Aruvian's R'search’s report – Analyzing the Indian Retail Industry 2007 - on the Indian Retail Industry is an in-depth and comprehensive cross industry ... potential development areas in the retail market in India. The process or entry options for FDI into Indian retail industry are examined in ...
June 2011
400 pages
India - Commerce and Industry Competitive Advantage Analysis
US$ 300.00
... objectives of growth and profitability. Aruvian's R'search presents India - Commerce and Industry Competitive Advantage Analysis which presents an absolute ... policies, economic scenario, and investment profile. This report on India’s commerce and the competitive advantages garnered by its industry presents an ...
June 2011
200 pages
Analyzing the Biofuel Industry in India
US$ 275.00
... brings you the complete guide to the Indian Biofuels Industry – Analyzing the Biofuel Industry in India. The report begins with an analysis of the ... starting on the fascinating journey of discovering the biofuels industry in India. The economics of biofuels, issues facing the industry, regulatory barriers as ...
June 2011
200 pages
Analyzing Fixed Line Telecommunication Industry in India
US$ 250.00
... fixed line telecommunication industry in India. The report begins with an analysis of the basics of the telecommunication industry and then moves on to analyze the industry in India. The report analyzes the ...
June 2011
60 pages
Consumer Electronics Industry in India
US$ 375.00
... mark on the consumer electronics industry. The impact of such trends on the consumer electronics industry is analyzed in Aruvian’s report Consumer Electronics Industry in India. The various consumer classes that are ...
June 2011
125 pages
Actos Bladder Cancer Concerns -Anti-diabetic Class Bracing For Newer Therapies
US$ 140.00
... diabetes class. Our discussion with key opinion leaders (KOLs) suggests that the recently issued warning by the USFDA (increased risk of bladder cancer ... on long term use of actos) would lead to restricted use of Actos. The use of Actos ... be much of a concern for Takeda. Actos sales in EU is just ...
June 2011
3 pages
Cardizem CD: Para IV For An Age Old Compound, Still Enjoys Limited Competition
US$ 350.00
Our recent study about the Cardizem CD Para IV litigation between Sun Pharma and Valeant ( ... 2012 (2) there is currently no competition for 360mg Cardizem CD and Sun Pharma will be the only generic ... Sun will be able to launch the generic of Cardizem CD upon receiving final USFDA approval including the launch ...
June 2011
3 pages
AUROBINDO'S, NATCO'S, WOCKHARDT'S PARA IV PIPELINE ANALYSIS
US$ 350.00
The attached report is a comprehensive study of Aurobindo’s, Natco’s & Woclhardts Para IV pipeline and likely upside from each of the opportunities. The report is a part of our recently introduced web based application – PARA IV Plus™.
June 2011
30 pages
Dr Reddy's PARA IV Pipeline Analysis
US$ 350.00
Dr Reddys has pipeline of ~20 Para IVs having branded sales of ~$24b. Among its Para IV pipeline the confirmed opportunities (branded sales ~$11.2b) are Exelon, Propecia, Zyprexa (20 mg), ... Nexium, Lipitor and Geodon. We expect PAT of ~$185m from the Dr. Reddy’s Para IVs which is ~3% of the current market Cap.
June 2011
21 pages
Lupin's PARA IV Pipeline Analysis
US$ 350.00
Lupin has pipeline of ~34 products having branded sales of ~$16b. Among its Para IV pipeline most lucrative opportunities are very few like that of Geodon, ... and Asacol. On other hand there are some Para IVs ...
June 2011
28 pages
Para IV presentation
US$ 350.00
A macro study on Indian Pharma Para IV litigations – a part of our recently introduced web based application - PARA IV Plus™ . This will provide you with a broad but meaningful insight to the prevalence of Indian Pharmaceutical companies in the Para IV space
June 2011
9 pages
RANBAXY'S PARA IV PIPELINE ANALYSIS
US$ 350.00
Ranbaxy has a pipeline of ~19 Para IV challenges, of which 12 are FTF’s. The total branded sales of these drugs under Para IV challenge by Ranbaxy is approximately $25b. Most of these Para ... offer decent upside. We expect Ranbaxy to generate a cumulative PAT of ~$950m from these Para IV opportunities, which is ...
June 2011
22 pages
Sun Pharma's Para IV Pipeline Analysis
US$ 350.00
Sun Pharma has the pipeline of ~29 Para IVs having branded sales of ~$25b. Among its Para IV pipeline the confirmed opportunities (branded sales of ~ $7.8b) are Gleevec, Namenda, Comtan, ...
June 2011
27 pages
DISHMAN - Back To Basics
US$ 90.00
We reiterate our Underperform rating on Dishman despite it’s higher than expected Q4 FY11 result. The result was ...
May 2011
5 pages
Lupin Looses Combivir – A Big Blow To An Already Weak FY12 Pipeline
US$ 140.00
... for generic Combivir (Lamivudine + Zidovudine). With this approval, Teva has been granted and Lupin has ... ), Teva will launch its generic in Q4CY11. Lupin will be able to enter only after the 180 ... all other generics as well. We reiterate our Underperform on Lupin with target price of Rs.360 on the back of (1) ...
May 2011
2 pages
Indian Baby Care Market Analysis
US$ 800.00
Single User PDF Format: US$ 800.00 Multi-User License: US$ 1,500.00 Hard Copy: US$ 1,000.00 CD-ROM: US$ 1,000.00 India is one of the most attractive retail destinations around the world and hence rep...
May 2011
60 pages
Indian Telecom Analysis (2008-2012)
US$ 800.00
Single User PDF Format: US$ 800.00
Multi-User License: US$ 1,000.00
Hard Copy: US$ 900.00
CD-ROM: US$ 900.00 Telecom industry in India has undergone a revolution during the past few ye...
May 2011
70 pages
